Literature DB >> 17676210

Actual antibiotic resistance pattern of Brucella melitensis in central Anatolia. An update from an endemic region.

Esra Tanyel1, Ahmet Y Coban, Suda T Koruk, Husniye Simsek, Serkan Hepsert, Osman S Cirit, Necla Tulek.   

Abstract

OBJECTIVE: To test in vitro susceptibilities of Brucella melitensis (B. melitensis) blood isolates obtained from an endemic region, by broth microdilution susceptibility test.
METHODS: Fifty blood isolates were tested with anti-brucella antibiotics, namely, tetracycline, gentamicin, streptomycin, ceftriaxone, ciprofloxacin, levofloxacin, ofloxacin, and rifampin. All of the clinical isolates belonged to the group of B. melitensis biotype-3. This study was performed at the Clinical Microbiology Laboratory of the Medical School of Ondokuz Mayis University, Samsun, Turkey, in 2005.
RESULTS: In terms of minimum inhibitory concentration-90 (MIC90) values, tetracycline (MIC90 0.25 microgram/mL) and rifampin (MIC90 0.5 microgram/mL) still continue to be the most effective antibiotics; however, ceftriaxone and streptomycin demonstrated higher MIC values, although they were still effective in vitro against B. melitensis strains with MIC90 of 8 microgram/mL.
CONCLUSION: All first line, and alternative antimicrobial agents could be used in various combinations in the treatment of human brucellosis. High MIC values of ceftriaxone and streptomycin are alarming, and should be closely monitored during the therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17676210

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  5 in total

1.  Antimicrobial susceptibility of Brucella melitensis isolates in Peru.

Authors:  Ryan C Maves; Rosa Castillo; Alfredo Guillen; Benjamin Espinosa; Rina Meza; Nereyda Espinoza; Gladys Núñez; Luis Sánchez; Jesús Chacaltana; David Cepeda; Sofía González; Eric R Hall
Journal:  Antimicrob Agents Chemother       Date:  2011-01-03       Impact factor: 5.191

2.  Identification and in vitro antimicrobial susceptibility of Brucella species isolated from human brucellosis.

Authors:  Rohaidah Hashim; Norazah Ahmad; Jama'ayah Mohamed Zahidi; B Y Tay; Azura Mohd Noor; Sakina Zainal; Hazwani Hamzah; S H Hamzah; T S Chow; P S Wong; K N Leong
Journal:  Int J Microbiol       Date:  2014-07-10

3.  Human Brucellosis in Rural Uganda: Clinical Manifestations, Diagnosis, and Comorbidities at Kabale Regional Referral Hospital, Kabale, Uganda.

Authors:  Kevin D Dieckhaus; Peterson S Kyebambe
Journal:  Open Forum Infect Dis       Date:  2017-11-01       Impact factor: 3.835

4.  In vitro antibiotic susceptibility testing of Brucella isolates from Egypt between 1999 and 2007 and evidence of probable rifampin resistance.

Authors:  Mohamed Abdel-Maksoud; Brent House; Momtaz Wasfy; Bassem Abdel-Rahman; Guillermo Pimentel; Gehan Roushdy; Erica Dueger
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-08-28       Impact factor: 3.944

5.  Identification and determination of antibiotic susceptibilities of Brucella strains isolated from patients in van, Turkey by conventional and molecular methods.

Authors:  Mehmet Parlak; Hüseyin Güdücüoğlu; Yasemin Bayram; Aytekin Çıkman; Cenk Aypak; Selçuk Kılıç; Mustafa Berktaş
Journal:  Int J Med Sci       Date:  2013-08-22       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.